CRISPR/Cas9 genome editing for neurodegenerative diseases
EXCLI Journal · 03.07.2023 · 22 · 567-582
DOI: 10.17179/excli2023-6155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 03.07.2023. Verfasst von Jafar Nouri Nojadeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ankara University Faculty of Medicine, Department of Medical Biochemistry, Ankara, Turkey. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gene therapy has emerged as a promising therapeutic strategy for various conditions, including blood disorders, ocular disease, cancer, and nervous system disorders. The advent of gene editing techniques has facilitated the ability of researchers to specifically target and modify the eukaryotic cell genome, making it a valuable tool for gene therapy. This can be performed through either in vivo or ex vivo approaches. Gene editing tools, such as zinc finger nucleases, transcription activator-like effector nucleases, and CRISPR-Cas-associated nucleases, can be employed for gene therapy purposes. Among these tools, CRISPR-Cas-based gene editing stands out because of its ability to introduce heritable genome changes by designing short guide RNAs. This review aims to provide an overview of CRISPR-Cas technology and summarizes the latest research on the application of CRISPR/Cas9 genome editing technology for the treatment of the most prevalent neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis, and Spinocerebellar ataxia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ankara University Faculty of Medicine, Department of Medical Biochemistry, Ankara, Turkey.
- The Graduate School of Health Sciences of Ankara University, Ankara, Turkey.
- Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
Zitieren
APA
Nouri Nojadeh, J., Bildiren Eryilmaz, N. S., & Ergüder, B. I. (2023). CRISPR/Cas9 genome editing for neurodegenerative diseases. EXCLI Journal, 22, 567-582. https://doi.org/10.17179/excli2023-6155
Vancouver
Nouri Nojadeh J, Bildiren Eryilmaz NS, Ergüder BI. CRISPR/Cas9 genome editing for neurodegenerative diseases. EXCLI Journal. 2023;22:567-582. doi:10.17179/excli2023-6155
BibTeX
@article{NouriNojadeh2023,
author = {Nouri Nojadeh, Jafar and Bildiren Eryilmaz, Nur Seren and Ergüder, Berrin Imge},
title = {CRISPR/Cas9 genome editing for neurodegenerative diseases},
journal = {EXCLI Journal},
year = {2023},
volume = {22},
pages = {567--582},
doi = {10.17179/excli2023-6155}
}
EUVIMED